Monday, November 23, 2009

Multiple Sclerosis Home>
Multiple Sclerosis News>
FDA updates Tysabri safety information

Font size
- A
- A
- A
Email This

Bookmark

Save

Receive a FREE Osteoarthritis of the knee pamphlet. Start here.

FDA updates Tysabri safety information

(Wall Street Journal) UPDATED 2009-09-21

The U.S. Food and Drug Administration has updated the safety information for the drug Tysabri to take into account the incidence of a rare brain infection. The new information warns patients that the risk of progressive multifocal leukoencephalopathy, or PML, appears to increase as the number of Tysabri infusions increase. For those patients who developed PML, the average number of infusions was 25. However, Tysabri's drugmaker points out that the overall risk for developing PML is still 1 in 1,000 patients. Read full story >

See all Multiple Sclerosis News

Font size
- A
- A
- A
Email This
Bookmark

Was this helpful? Yes
Save

Note: All clinical content on this site is physician-reviewed, except material generated by our community members.

Featuring Content From:

By using this service, you accept our Terms of Use. Please read them. The consumer health information on MultipleSclerosisCentral.com is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2005-2009. The HealthCentral Network, Inc. All rights reserved.

We comply with the HONcode standard for trustworthy health information: verify here.